Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of AMG 334 in migraine prevention
2013-005311-27Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erenumab in chronic migraine and migraine, sponsored by Amgen. Primary endpoint: Subject incidence of adverse events. Started Mar 2014; status: completed.
02
Drugs
erenumab
03
Conditions
chronic migrainemigraine
Beyond the preview
Go deeper on 2013-005311-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005311-27.